Roche Holding AG said Monday that it has extended the offer period for its planned takeover of biotechnology company Spark Therapeutics to Dec. 16.
Swiss pharmaceutical company Roche said the offer was extended to provide additional time for the U.S. Federal Trade Commission and the U.K. Competition and Markets Authority to complete their reviews of the pending acquisition.
The period for Roche’s offer of $114.50 per share has been extended several times and was set to expire on Dec. 10.
As of Dec. 6, around 14.9% of Spark’s outstanding shares had been tendered, according to Roche.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.